Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Sonja Zweegman"'
Autor:
Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrian Alegre Amor, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Besisik, Michele Cavo, Javier De La Rubia Comos, Meletios A. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Facon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hajek, Guner Hayri Ozsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Stefan Knop, Marie-Christine Kyrtsonis, Juan Jose Lahuerta, Xavier Leleu, Carmen Martinez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique Minnema, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlivan, Ludek Pour, Henk Th.J. Roerdink, Laura Rosinol Dacsh, Hans Salwender, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tulin Tuglular, Ali Unal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group
instname
APOLLO Trial Investigators 2021, ' Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 6, pp. 801-812 . https://doi.org/10.1016/S1470-2045(21)00128-5
LANCET ONCOLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
The Lancet. Oncology, 22(6), 801-812. Lancet Publishing Group
The Lancet Oncology, 22(6), 801-812. Lancet Publishing Group
Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c27bb717191298826d5623e5b11470
http://hdl.handle.net/10261/261314
http://hdl.handle.net/10261/261314
Autor:
Pieter Sonneveld, Henk M. Lokhorst, Bronno van der Holt, Emelie Asselbergs, Marie José Kersten, Okke de Weerdt, Marinus van Marwijk Kooy, Edo Vellenga, Monique C. Minnema, Sarah Lonergan, Annemiek Broijl, Sonja Zweegman, Antonio Palumbo, Ruth Wester
Publikováno v:
Wester, R, Van Der Holt, B, Asselbergs, E, Zweegman, S, Kersten, M J, Vellenga, E, Van Marwijk Kooy, M, De Weerdt, O, Minnema, M, Lonergan, S, Palumbo, A, Lokhorst, H, Broijl, A & Sonneveld, P 2019, ' Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial ', Haematologica, vol. 104, no. 11, pp. 2265-2273 . https://doi.org/10.3324/haematol.2018.205476
Haematologica, 104(11), 2265. Ferrata Storti Foundation
Haematologica, 104(11), 2265-2273. Ferrata Storti Foundation
Haematologica
Haematologica, 104(11), 2265. Ferrata Storti Foundation
Haematologica, 104(11), 2265-2273. Ferrata Storti Foundation
Haematologica
This is a phase II dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The results of four dose levels ar
Autor:
Richard Labotka, Meletios-Athanasios Dimopoulos, Jeffrey Matous, Suman Kambhampati, Roman Hájek, Sosana Delimpasi, Lionel Karlin, Jesus G. Berdeja, Andrzej Pluta, Kaveri Suryanarayan, Petr Pavlicek, Ajeeta B Dash, Robert Z. Orlowski, Argiris Symeonidis, Sebastian Grosicki, Sonja Zweegman, Jan Straub, Pawel Robak, Cyrille Touzeau, Luděk Pour, Viralkumar Bhanderi, Philip Twumasi-Ankrah
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S154-S155
Background: Proteasome inhibitors (PIs) & monoclonal antibodies are backbones of RRMM treatment;Ixa is approved with lenalidomide-dex for pts with ≥1 prior therapy, & Dara is approved in various regimens, including with bortezomib-dex (DVd). In CAS
Autor:
Annemiek Broijl, Laurens E. Franssen, Pieter Sonneveld, Paula F. Ypma, Peter E. Westerweel, Gerard M. J. Bos, Inger S. Nijhof, Laura M. Faber, Jeroen F. van Velzen, Henk M. Lokhorst, Berris van Kessel, Rimke Oostvogels, Dick Johan van Spronsen, Aart Beeker, Mark-David Levin, Ellen van der Spek, Niels W.C.J. van de Donk, Reinier Raymakers, Harry R. Koene, Tuna Mutis, Sonja Zweegman, Saskia K. Klein, Andries C. Bloem
Publikováno v:
Blood, 128(19), 2297-2306. American Society of Hematology
Nijhof, I S, Franssen, L E, Levin, M-D, Bos, G M J, Broijl, A, Klein, S K, Koene, H R, Bloem, A C, Beeker, A, Faber, L M, van der Spek, E, Ypma, P F, Raymakers, R, van Spronsen, D-J, Westerweel, P E, Oostvogels, R, van Velzen, J, van Kessel, B, Mutis, T, Sonneveld, P, Zweegman, S, Lokhorst, H M & van de Donk, N W C J 2016, ' Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma ', Blood, vol. 128, no. 19, pp. 2297-2306 . https://doi.org/10.1182/blood-2016-07-729236
Blood, 128(19), 2297-2306. The American Society of Hematology
Nijhof, I S, Franssen, L E, Levin, M-D, Bos, G M J, Broijl, A, Klein, S K, Koene, H R, Bloem, A C, Beeker, A, Faber, L M, van der Spek, E, Ypma, P F, Raymakers, R, van Spronsen, D-J, Westerweel, P E, Oostvogels, R, van Velzen, J, van Kessel, B, Mutis, T, Sonneveld, P, Zweegman, S, Lokhorst, H M & van de Donk, N W C J 2016, ' Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma ', Blood, vol. 128, no. 19, pp. 2297-2306 . https://doi.org/10.1182/blood-2016-07-729236
Blood, 128(19), 2297-2306. The American Society of Hematology
The prognosis of multiple myeloma (MM) patients who become refractory to lenalidomide and bortezomib is very poor, indicating the need for new therapeutic strategies for these patients. Next to the development of new drugs, the strategy of combining
Autor:
Sandra Croockewit, Pieter Sonneveld, Kazem Nasserinejad, Paula F. Ypma, Sonja Zweegman, Esther G. M. de Waal, Annemieke Broijl, Monique C. Minnema, Harry R. Koene, Ka Lung Wu, Marie José Kersten, Gerard M. J. Bos, Stefan Schönland, M Ron Schaafsma, Bouke P. C. Hazenberg, Lidwien Tick, Ute Hegenbart, Philip Vlummens, Nicolaus Kröger
Publikováno v:
Haematologica
Haematologica-the Hematology Journal, 104(11), 2274-2282. Ferrata Storti Foundation
Minnema, M C, Nasserinejad, K, Hazenberg, B, Hegenbart, U, Vlummens, P, Ypma, P F, Kröger, N, Wu, K L, Kersten, M J, Schaafsma, M R, Croockewit, S, de Waal, E, Zweegman, S, Tick, L, Broijl, A, Koene, H, Bos, G, Sonneveld, P & Schönland, S 2019, ' Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: Results of the multicenter HOVON 104 trial ', Haematologica, vol. 104, no. 11, pp. 2274-2282 . https://doi.org/10.3324/haematol.2018.213900
Haematologica, 104(11), 2274-2282. Ferrata Storti Foundation
Haematologica, 104(11), 2274. Ferrata Storti Foundation
Haematologica, 104(11), 2274-2282. FERRATA STORTI FOUNDATION
Haematologica, 104, 11, pp. 2274-2282
Haematologica, 104, 2274-2282
HAEMATOLOGICA
Haematologica-the Hematology Journal, 104(11), 2274-2282. Ferrata Storti Foundation
Minnema, M C, Nasserinejad, K, Hazenberg, B, Hegenbart, U, Vlummens, P, Ypma, P F, Kröger, N, Wu, K L, Kersten, M J, Schaafsma, M R, Croockewit, S, de Waal, E, Zweegman, S, Tick, L, Broijl, A, Koene, H, Bos, G, Sonneveld, P & Schönland, S 2019, ' Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: Results of the multicenter HOVON 104 trial ', Haematologica, vol. 104, no. 11, pp. 2274-2282 . https://doi.org/10.3324/haematol.2018.213900
Haematologica, 104(11), 2274-2282. Ferrata Storti Foundation
Haematologica, 104(11), 2274. Ferrata Storti Foundation
Haematologica, 104(11), 2274-2282. FERRATA STORTI FOUNDATION
Haematologica, 104, 11, pp. 2274-2282
Haematologica, 104, 2274-2282
HAEMATOLOGICA
This prospective, multicenter, phase II study investigated the use of four cycles of bortezomib-dexamethasone induction treatment, followed by high-dose melphalan and autologous stem cell transplantation (SCT) in patients with newly diagnosed light c
Autor:
Francesco Passamonti, Moshe Talpaz, Ruben A. Mesa, Derek Tang, Alessandro M. Vannucchi, Sonja Zweegman, Jean-Jacques Kiladjian, Nicolaas Schaap, Jun Zhang, Claire N. Harrison, Peiwen Yu, John Mascarenhas, Xiaomei Ye, Srdan Verstovsek, Shelonitda Rose
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S328
Context: MF is characterized by anemia, progressive splenomegaly, and debilitating constitutional symptoms. Fedratinib is a selective JAK2 inhibitor approved in the US for adult patients with intermediate-2 or high-risk MF. Fedratinib was assessed in
Autor:
Sonja Zweegman, Srdan Verstovsek, Francesco Passamonti, Jun Zhang, Nicolaas Schaap, Ruben A. Mesa, Claire N. Harrison, Alessandro M. Vannucchi, Moshe Talpaz, Shelonitda Rose, Carrie Brownstein, Tymara Berry, Jean-Jacques Kiladjian
Publikováno v:
Blood. 134:668-668
Introduction: Cytopenias are a leading cause of ruxolitinib (RUX) discontinuation for patients (pts) with myelofibrosis (MF). Though RUX 5 mg BID is recommended for pts with platelet (PLT) counts of 50 to Methods: JAKARTA and JAKARTA2 enrolled adult
Autor:
Claire N. Harrison, Mingyu Li, Srdan Verstovsek, Tymara Berry, Nicolaas Schaap, Eric Jourdan, Moshe Talpaz, Torsten Gerike, Alessandro M. Vannucchi, Richard T. Silver, Harry C. Schouten, Sonja Zweegman, Ruben A. Mesa, Jean-Jacques Kiladjian, Shelonitda Rose, Francesco Passamonti, Carrie Brownstein
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S356
Autor:
Marie José Kersten, Bronno van der Holt, Sonja Zweegman, Antonio Palumbo, Okke de Weerdt, Henk M. Lokhorst, Sarah Lonergan, Edo Vellenga, Pieter Sonneveld, Emilie Asselbergs, Marinus van Marwijk-Kooy, Annemiek Broyl
Publikováno v:
Blood, 125(3), 449-456. AMER SOC HEMATOLOGY
Blood, 125(3), 449-456. American Society of Hematology
Sonneveld, P, Asselbergs, E, Zweegman, S, van der Holt, B, Kersten, M J, Vellenga, E, van Marwijk-Kooy, M, Broyl, A, de Weerdt, O, Lonergan, S, Palumbo, A & Lokhorst, H M 2015, ' Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma ', Blood, vol. 125, no. 3, pp. 449-456 . https://doi.org/10.1182/blood-2014-05-576256
Blood, 125(3), 449-456. American Society of Hematology
Sonneveld, P, Asselbergs, E, Zweegman, S, van der Holt, B, Kersten, M J, Vellenga, E, van Marwijk-Kooy, M, Broyl, A, de Weerdt, O, Lonergan, S, Palumbo, A & Lokhorst, H M 2015, ' Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma ', Blood, vol. 125, no. 3, pp. 449-456 . https://doi.org/10.1182/blood-2014-05-576256
This multicenter phase 2 study of the European Myeloma Network investigated the combination of carfilzomib, thalidomide, and dexamethasone (KTd) as induction/consolidation therapy for transplant-eligible patients with previously untreated multiple my
Autor:
Robyn M. Scherber, Claire N. Harrison, Ruben A. Mesa, Stefanie Slot, Junqing Xu, Jean-Jacques Kiladjian, Zefeng Xu, Pablo J. Muxi, Chiara Paoli, Harry C. Schouten, Lydia Roy, Peter A. W. te Boekhorst, Robert Peter Gale, Norman Maldonado, Thomas Lehmann, Karin Bonatz, Maria Luisa Ferrari, Federico Sackmann, Jean Christophe Ianotto, Peihong Zhang, Giovanni Barosi, Alessandro Rambaldi, Bjorn Andreasson, Peter L. Johansson, Xiujuan Sun, Allison H. Scotch, Ana Kerguelen Fuentes, Jean-Yves Cahn, Deepti Radia, Suzan Commandeur, Zhijian Xiao, Jan Samuelsson, Heidi E. Kosiorek, Francisco Cervantes, Yue Zhang, Gabriel Etienne, Heike L. Pahl, Françoise Boyer, Martin Griesshammer, Francesco Passamonti, Konstanze Döhner, Gunnar Birgegård, Sonja Zweegman, Carlos Besses, Alessandro M. Vannucchi, Dana Ranta, Frank Stegelmann, Dolores Hernández-Maraver, Amylou C. Dueck, Holly L. Geyer, Tiziano Barbui, Andreas Reiter
Publikováno v:
Leukemia Research, 63, 34-40. Elsevier Ltd.
Scotch, A H, Kosiorek, H, Scherber, R, Dueck, A C, Slot, S, Zweegman, S, Boekhorst, P A W T, Commandeur, S, Schouten, H, Sackmann, F, Fuentes, A K, Hernández-Maraver, D, Pahl, H L, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J C, Ranta, D, Roy, L, Cahn, J Y, Harrison, C N, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, P L, Barbui, T, Barosi, G, Vannucchi, A M, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, M L, Rambaldi, A, Samuelsson, J, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, J J, Zhang, P, Gale, R P, Mesa, R A & Geyer, H L 2017, ' Symptom burden profile in myelofibrosis patients with thrombocytopenia : Lessons and unmet needs ', Leukemia Research, vol. 63, pp. 34-40 . https://doi.org/10.1016/j.leukres.2017.10.002
Leukemia Research, 63, 34-40. Elsevier Limited
Leuk Res
Scotch, A H, Kosiorek, H, Scherber, R, Dueck, A C, Slot, S, Zweegman, S, Boekhorst, P A W T, Commandeur, S, Schouten, H, Sackmann, F, Fuentes, A K, Hernández-Maraver, D, Pahl, H L, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J C, Ranta, D, Roy, L, Cahn, J Y, Harrison, C N, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, P L, Barbui, T, Barosi, G, Vannucchi, A M, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, M L, Rambaldi, A, Samuelsson, J, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, J J, Zhang, P, Gale, R P, Mesa, R A & Geyer, H L 2017, ' Symptom burden profile in myelofibrosis patients with thrombocytopenia : Lessons and unmet needs ', Leukemia Research, vol. 63, pp. 34-40 . https://doi.org/10.1016/j.leukres.2017.10.002
Leukemia Research, 63, 34-40. Elsevier Limited
Leuk Res
Myelofibrosis is a myeloproliferative neoplasm associated with progressive cytopenias and high symptom burden. MF patients with thrombocytopenia have poor prognosis but the presence of thrombocytopenia frequently precludes the use of JAK2 inhibitors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022b1a49d48b9e484baa96dcb56756c9
http://hdl.handle.net/11383/2066806
http://hdl.handle.net/11383/2066806